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D 4.12
General Issues Relating to Endovascular
Treatment
D 4.12.1
Need for Surveillance
As with surgical bypass grafts, it is likely that surveil-
lance and repeat intervention would improve the
assisted primary patency of PTA. In infrainguinal
PTA, primary and assisted primary patency rates
approximate each other because re-intervention is
attempted in a relatively small proportion of PTA
patients.J.2.3,4 For example, Gallino et al' repeated PTA
on only 14% of failed or failing femoropoliteal PTA
whereas Capek et aP reported a re-intervention rate of
only 8%.4 However, when repeat PTA is performed in
a higher percentage of patients, patency can be
Table 5-1: Ideal characteristics of stents and delivery systems
Characteristics
improved. For example, Harris et a15, in a series of PTA
performed by surgeons, used surveillance and re-
intervention as needed with 57% primary 6-month
patency and 82% assisted primary 6-month patency.
Although the ability of periprocedural duplex to
predict ultimate PTA durability is controversial.v"
duplex ultrasound may be useful in an appropriate
longitudinal postprocedure surveillance program.
Vroegindewij et al? found that duplex ultrasound is
sensitive in detecting restenosis and, along with
clinical and other noninvasive follow-up, it could
be very useful in augmenting the durability of
femoropopliteal PTA.
D 4.12.2
Comparison of Available Stents
Currently all intravascular stents in clinical use are
permanent and metallic. Stent designs and technolo-
gies used for managing peripheral vascular disease
arc continually evolving. The availability of and
approved indications for specific stents vary by coun-
try. The ideal stent and delivery system should have
the following characteristics'wu-P:
Stents are generally stratified into balloon-expand-
able (eg, Palrnaz, Strecker) and self-expandable. The
self-expandable stents are generally based on one of
two designs: (1) spring-open expansion after removal
of restraint (eg, Wallstent) or (2) thermal memory
expansion at body temperature (eg, Memotherm,
Nitinol stents). Currently thermal stents are construct-
ed of Nitinol (nickel-titanium alloy), and self-expand-
Allow for efficiency in and ease of deployment
Use percutaneous technique
- have a low-profile delivery system
- have a high expansion ratio
Be available in a wide range of diamet ers and lengths
Have longitudinal flexibility
Ability to be optimally and precisely positioned
- have high rad io-opacity
- have minim al foreshortening
. - ability to be retr ieved or repositioned
- no slippage of stent on balloons; rupture-resistant balloon (for stent/balloon delivery system)
Yield durable clinical results
Reliably oppose elastic recoil, stenosis, or dissection flap
Be thromboresistant
Resist restenosis
Resist comp ression , deformation, or fracture
Bebiologically compatible, to resist infection and minimise inflammatory reaction
Be incorporated into vessel wall with thin neointima/functional endothelium
Do not emboli se or migrate
Be inexpensive
Allow for noninvasive imaging and follow-up with CT, MRA, and ultrasound.
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able spring and balloon-expandable stents are gener-
ally constructed from stainless steel. The long-term
effects of stent design, such as potential for develop-
ment of new intimal hyperplasia, are incompletely
understood. This choice of a particular stent type
tends to be most related to anatomy and ease of place-
ment (eg, flexibility) and cost considerations (eg, min-
imising the number of stents needed to treat the target
lesions). 10,11,12,13,14,15,16,17
D 4.12.3
Role of Endovascular Procedures Other Than
Angioplasty and Stenting
The role of directional and rotational atherectomy for
treating atheromatous occlusions or stenoses remains
circumscribed. These devices do not appear to offer
improved clinical and haemodynamic outcomes or
superior durability compared with PTA.9,18,19
Percutaneous atherectomy may have utility as a niche
device in highly selected patients, as an adjunct to
PTA for treating occlusive flaps or eccentric calcified
plaque.18.20 Similarly, the use of lasers for crossing or
debulking occlusive lesions generally has not been
accepted as cost effective. As noted earlier, in D 4.9.1,
Factors Affecting the Outcome of Femoropopliteal
Angioplasty, laser and atherectomy do not appear to
be broadly applicable to the infrapopliteal arteries (see
p 5192).21,22.23
D 4.12.4
Role of Thrombolysis in CLI
The role of thrombolysis for treating chronic iliac and
femoropoliteal artery occlusions in patients with
chronic CLI is controversial. Some authors favour lysis
before stent placement24.25,26 and others favour stenting
alone." Data on comparative costs and morbidity,
including the relative incidence of complications such
as haemorrhage and distal embolisation, are lacking.
Differences in patient selection, techniques, and
reporting have hindered comparison of these two
approaches.24,25,28
Critical Issue 37: Role of thrombolysis in chronic
iliac lesions
There is a need for studies to determine whether
preliminary catheter-directed thrombolytic therapy
enhances the efficacy or safety of angioplasty and
stenting of chronic iliac occlusions.
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D 4.12.5
Incidence and Management of Complications
The incidence and management of complications after
endovascular intervention is detailed in B 4.3.7,
Complications of Endovascular Procedures (p 594)
and is not repeated here.
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04.13
Adjuvant Therapy After Revascularisation
D 4.13.1
Introduction
Vascular and endovascular procedures suffer a risk of
failure, either early, intermediate, or late. Several fac-
tors affect this risk, and the incidence differs consider-
ably between various types of procedures. The main
causes of failure can be categorised as (1) early-tech-
nical flaws or low flow or increased thrombogenicity;
(2) intermediate (6-24 months)-intimal hyperplasia;
and (3) late-progression of atheromatous disease.
Regarding open vascular procedures, factors that
affect failure are the use of autogenous versus syn-
thetic vascular conduits, endarterectomy versus
bypass procedures, and the location of the procedure,
for example, an aortic procedure compared with a dis-
tal reconstruction. This also relates to differences in
the calibre of the recipient arteries, occlusive lesions in
the inflow or outflow vessels, and the capacity of the
collateral circulation.
Bypass patency also depends on the calibre and
length of graft to be used. Progression of disease and
risk factors such as smoking and blood lipids have a
major implication on patency. At one extreme, an aor-
tobifemoral graft with a perfect outflow carries at least
a 90% 'l-year patency, whereas the corresponding fig-
ure for a prosthetic femorodistal bypass with restrict-
ed run-off might be 30% or even less. Technical prob-
lems, encountered during surgery or caused by sur-
gery, also greatly influence the immediate outcome of
the procedure. The same kind of factors presumably
influence the outcome of endovascular procedures.
However, some of these procedures have only come
into use recently, which means that less knowledge
exists on the incidence and magnitude of the prob-
lems.
Current adjuvant pharmacological treatment aims
to reduce either early failures due to thrombosis, inter-
mediate graft occlusions due to intimal hyperplasia, or
further progression of atherosclerosis. Even though
vein grafts are at much less risk of developing occlu-
sions than synthetic grafts, it is reasonable to discuss
them together because most of the expected problems
are of the same kind, though not of the same magni-
tude. Various pharmacological agents are in use to
prevent thrombosis. The two most important cate-
gories are antiplatelet therapy and anticoagulation.
Recently also, prostanoids and nitric oxide have been
tried clinically. Although exerting antiplatelet effects,
these compounds are discussed separately from
antiplatelet therapy.
D 4.13.2
Antiplatelet Therapy
Acetylsalicylic acid
Acetylsalicylic acid (ASA) has been recommended on
its own merits for reducing thrombotic events in all
patients with PAD (see Recommendation 28, p S71).
This discussion focuses on the use of ASA to assist
the patency of revascularisation procedures.
Acetylsalicylic acid has been investigated in ran-
domised clinical trials, either alone or in combination
with dipyridamole. In a 1982 report, patients with
PTFE grafts for either above-knee or below-knee
femoropopliteal bypass procedures were randomised
to either placebo, ASA alone. or ASA plus dipyri-
damole, starting preoperatively,' For below-knee
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